X

Drug Profile

Research programme: serotonin 2A/C receptor agonists - Bright Minds Biosciences

Alternative Names: 5-HT2A/C agonists receptor agonists - Bright Minds Biosciences

Latest Information Update: 19 Feb 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bright Minds Biosciences
Class Non-opioid analgesics
Mechanism of Action 5-HT2C serotonin receptor agonists; Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Pain

Most Recent Events

05 Feb 2021 Bright Minds Biosciences and National Institutes of Health (USA) agree to co-develop serotonin 2A/C receptor agonists for Pain
05 Feb 2021 Bright Minds Biosciences has patent protection for psychedelic compounds
05 Feb 2021 Preclinical trials in Pain in Canada (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com